Vinblastine Sulfate
Brand Names: Vinblastine Sulfate Generic
Methodology & AI Transparency ⓘ
Vinblastine Sulfate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Indications and usage:: Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I.
- 2 Real-world patient consensus: Tracked across 12 patient dosage logs with a 88% satisfaction benchmark (RxCUI 239178).
- 3 Typical cash cost range: 30-day cash pricing ranges from $141.34 discount cash to $346.28 walk-in retail (NADAC $3.2800/unit).
- 4 Top reported side effects / signs: Most commonly reported Vinblastine Sulfate tolerability events: nausea (7.6%), headache (7.7%), dizziness (5.4%).
Ask our AI Specialists anything about Vinblastine Sulfate
Vinblastine Sulfate Mechanism, CYP450 Pathways & DailyMed Monograph
Indications and usage:: Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies ; Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) ; Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) ; Histiocytic lymphoma ; Mycosis fungoides (advanced stages) ; Advanced carcinoma of the testis ; Kaposi’s sarcoma ; Letterer-Siwe disease (histiocytosis X) II.
CLINICAL PHARMACOLOGY: Experimental data indicate that the action of vinblastine sulfate is different from that of other recognized antineoplastic agents. Tissue-culture studies suggest an interference with metabolic pathways of amino acids leading from glutamic acid to the citric acid cycle and to urea. In vivo experiments tend to confirm the in vitro results. A number of studies in vitro and in vivo have demonstrated that vinblastine sulfate produces a stathmokinetic effect and various atypical mitotic figures.
Pharmacokinetic profiling of Vinblastine Sulfate demonstrates an elimination half-life of Biphasic clearance with 8–20 hr terminal t½ under Vinblastine Sulfate maintenance with Complete (~100%) parenteral systemic delivery for Vinblastine Sulfate (1 mg/mL Injection) systemic bioavailability; clearance proceeds via hepatic enzymatic processing and renal clearance proportional to creatinine clearance (vinblastine sulfate), reaching clinical onset within rapid intravascular/parenteral onset within 15–45 minutes after vinblastine sulfate administration.
Titration schedules for Vinblastine Sulfate (1 mg/mL Injection → Individualized Vinblastine Sulfate continuation schedule per specialist review) require excluding contraindications: vinblastine sulfate is contraindicated in patients who have significant granulocytopenia unless this is a result of the disease being treated.; it should not be used in the presence of bacterial infections.; such infections must be brought under control prior to the initiation of therapy with vinblastine sulfate.; real-world patient logs highlight headache (7.7% of reports), nausea (7.6% of reports), fatigue (5.6% of reports) alongside a 88.00% Worth-It consensus.
Accelerated hepatic clearance from strong CYP induction may require monitoring for subtherapeutic Vinblastine Sulfate efficacy.
Assess baseline hepatic panels and interacting prescriptions when starting Vinblastine Sulfate (vinca alkaloid).
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- CONTRAINDICATIONS: Vinblastine sulfate is contraindicated in patients who have significant granulocytopenia unless this is a result of the disease being treated.
- It should not be used in the presence of bacterial infections.
- Such infections must be brought under control prior to the initiation of therapy with vinblastine sulfate.
Logged Side-Effect Incidence (12 Reports)
Vinblastine Sulfate Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Vinblastine Sulfate)
Human clinical trial evidence for Vinblastine Sulfate is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Vinblastine Sulfate Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.2800/unit (~$98.40/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $346.28 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 12 Anonymous DotMD Community Micro-Logs | $141.34 / mo | View logs ↓ |
Vinblastine Sulfate Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Vinblastine Sulfate RxNorm Concept ID | 239178 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.2800 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $346.28 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $141.34 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 88.00% Worth It (12 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Vinblastine Sulfate Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Vinblastine Sulfate integrating DailyMed SPL (2025-04-15), CMS NADAC ($3.2800/unit), and 12 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Vinblastine Sulfate community threads and patient logs by age, biological sex, dosage, and treatment duration.